Benzinga | Mar 8, 2021 08:36AM EST

Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development

* Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma.

* The company cited challenges related to the pandemic.

* The study was assessing the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in combination with nivolumab.

* A preliminary analysis of results from 10 subjects indicated that SER-401 was safe and well-tolerated.

* No patients were enrolled in the FMT portion of the study.

* Subjects currently enrolled in the study will complete the study protocol.

* Price Action: MCRB shares gained 0.73% at $19.2 in premarket trading on the last check Monday.